Meghan Rivera

Step into the future of inclusive patient recruitment with Parexel's very own Patrick Grimes at PharmaSUG! Join us for "Leadership Skills LS-134: Recruiting Neurodivergent Candidates using the Specialisterne Approach." Learn how embracing diversity can enrich your team's culture and impact. Date for the diary. May 20th Monday, 8:30 AM - 8:50 AM Key Ballroom 10 If you want to work in an inclusive environment, that is always patient-focused, dive deeper here: https://jobs.parexel.com #ParexelWithHeart #LeadershipDevelopment #InclusivePatientRecruitment #StatsProgramming #StatisticalProgramming #PharmaSUG

2

❔ How do we position regional and community sites for success and mitigate risks for sponsors? ❔ In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. 🚧 That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/g7Tzd3t2 #ResearchSites #Oncology #NovelInsights

4

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/gfibr9S4 #ParexelBiotech #ResearchSites #Oncology #NovelInsights

2

The Psychopharmacologic Drugs Advisory Committee (PDAC), a group of independent experts which advises the FDA, yesterday recommended not to approve MDMA for PTSD. Several companies, including Lykos Therapeutics, are currently developing MDMA, for a range of mental health disorders, in this case, PTSD in veterans. In PDAC's opinion, MDMA combined with psychological intervention to treat PTSD in adults was not effective and the risks outweighed the benefits regarding the FDA's proposed risk evaluation and mitigation strategy (REMS). Although PDAC's guidance to the FDA is not binding, it typically follows it. This is the first psychedelics drug application to be submitted to the FDA for a mental health condition. Psychedelics biotech will be watching keenly at the FDA's decisions because the outcome will either be a game changer or a death knell for investment into the research space. In the US, ~13 million people live with PTSD, and existing treatments, including SSRIs, have been hit and miss. New treatment options are desperately needed. The decision date is Sunday 11th August 2024. Everything crossed for you Lykos Therapeutics 🤞🏾🤞🏾 #psychedelic #mdma #ptsd #lykostherapeutics #mapsbc #mentalhealth #mentalhealthconditions #fda

5

Still soaking up the last moments of summer, but it’s time to mark our calendars for the Pharma & Patient USA meeting this fall! Let's come together to discuss how we elevate patient voices and advance patient interests through stronger #patientadvocacy engagements and cross-functional partnerships. See you there! #teamwork #profoundimpact #makingpeoplesmile

95

2 Comments

Because the health of our planet matters

3

This content is intended for U.S. audiences only. The countdown to Chicago is on, as we gear up for #ASCO24 in less than two weeks! For the first time, @AstraZeneca will headline not one, but TWO back-to-back plenary sessions in LUNG as well as a late-breaking study in BREAST. Our team is focused on treating cancers at earlier stages and across subtypes while advancing medicines and combination therapies that attack the disease from all angles, evidenced by our strong, diverse research to be presented in Chicago. Behind every data point is a patient, who deserves a personalised therapy that will give them a longer and healthier life. For each one, we’re pushing the boundaries of science, and I can’t wait to highlight our research advances in the coming weeks. Stay tuned! 🔬 For a more detailed preview of our #ASCO24 data presentations, please see our press release https://lnkd.in/ehH7tqFc #CancerResearch #oncology #MedicalAdvancements

224

3 Comments

As we step into Pride Month, I want to take a moment to celebrate and support the LGBTQIA+ community. 🌈 Pride is more than just a celebration; it’s a powerful statement about love, identity, and the freedom to be oneself without fear. It’s about recognizing the struggles, honoring the courage, and supporting the rights of the LGBTQIA+ community. As an ally, I stand in solidarity with my LGBTQIA+ friends, colleagues, and the global community. I am committed to learning, listening, and lending my voice to advocate for inclusivity and diversity in all spaces. How can you become an ally, you ask? 😇 There are so many things you can do to be a better ally. 1. Educate yourself. 2. Listen and learn. 3. Be mindful of pronouns. 4. Practice inclusivity when you address the room. 5. Give up those “jokes” that are hurtful to the community. 6. Shame those movies that make fun of the community in a slapstick stereotypical way. 7. Call out discrimination when you see one. 8. Be humble, learn from mistakes, challenge your biases. 9. Support LGBTQIA+ causes. 10. If you are a reader like me, incorporate books by authors from LGBTQIA+ community in your bookshelf. (You can always ask me if you need reading recommendations) And if you are still on the fence about becoming an ally, no pressure. I hope you become one, someday. Till then, be open minded, be supportive. Otherwise, just get out of the way of progress, equality and equity. Let’s use this month to reflect on how we can all contribute to a world where everyone can live authentically and love freely. Let’s continue to educate ourselves, speak up against discrimination, and celebrate the beautiful spectrum of human experience. Happy Pride Month! #PrideMonth #Inclusion #Diversity #Allyship #archesintherainbow Chandra Duraiswamy

54

1 Comment

At the National Pharmaceutical Council, our culture supports growth and drives excellence. Today, we had an insightful team discussion on embracing work-life harmony by implementing 7 "chakra-inspired" energy-management actions (see below). Our LEGO mandalas (designed by me!) were the perfect physical representation of how we can bring our best selves to work. I am proud of the team for their authenticity during this time of play and reflection.   🔴 Root: Build a foundation with morning planning and prioritization 🔶Sacral: Prioritize creativity by setting aside time for focused, creative work ☀️Solar Plexus: Boost confidence by embodying a bias for action 💚Heart: Assume positive intent and offer grace to others 🗣Throat: Use your voice to speak up and speak your truth 👁️‍🗨️Third-eye: Connect with your intuition by taking breaks during the workday 🎆Crown: Disconnect from work with an end-of-day wind-down ritual Kimpossibility Creating Playful Possibility

61

15 Comments

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

1

Getting a lot of positive reaction with our new white paper on Rare disease Launch Excellence..see below.

43

1 Comment

“Inclusion is what we do, diversity is what we get when we’re inclusive, and equity is what we want.” These are the most powerful words I heard last week at the Fierce Pharma PR and Communications conference where DEI was a center-stage topic. As a queer, hispanic woman in STEM and first-generation college student, I re-appreciated the significant role that #Diversity, #Equity, and #Inclusion (#DEI) plays in the workspace. I was also educated on some of the major challenges of implementing effective DEI programs within the workforce. Here's what I learned. 1. DEI faces an Image Problem - Karen Boykin-Towns, who has had extensive experience at Pfizer and advisory roles at FGS Global, American Airlines, and L’Oréal, emphasized that DEI initiatives often face an image problem. DEI programs are perceived as benefiting "only the few," leading to skepticism and resistance. Instead, we need to perceive these initiatives as benefitting everyone because everyone benefits from an inclusive work space. 2. We need to focus on outcomes, not just numbers - Boykin-Towns also pointed out that the focus on mere numbers rather than genuinely diversifying spaces has contributed to the DEI challenge. Companies should instead implement impactful DEI approaches tailored to their specific contexts, rather than view diversity as a quota. She underscored that while diversity groups within companies often become mere “activities committees,” there needs to be a consistent effort to address DEI issues in addition to celebrating diversity through social activities. 3. We fear being "cancelled"- Another pressing issue discussed is the fear and hesitation surrounding DEI conversations. People often feel underqualified or afraid of saying the "wrong" thing, which hinders meaningful dialogue and progress. Boykin-Towns stressed the need for compassion and grace towards those making an effort, as well as the importance of financial inclusion and diversifying clinical trials beyond tokenism. Ultimately, achieving equity is about treating people fairly and inclusively, which in turn fosters true diversity.

22

A bittersweet wave of nostalgia washes over me as Facebook Memories resurrects the past - the landmark GSK oncology launch press release (Year 2011). As I sit in quiet reflection, I'm struck by the weight of what could have been. In those fleeting moments, GSK's oncology division blazed a trail of hope across India's healthcare landscape. Their vision wasn't just about market share; it was a beacon of patient-centric care in a realm where lives hang in the balance. The senior leadership's foresight and commitment to India were nothing short of revolutionary. But like a shooting star, this brilliance was tragically short-lived. The torch they lit - one of accessibility and genuine care for Indian patients - flickered and faded as other multinational corporations failed to carry it forward. This stark reminder should serve as both a challenge and a wake-up call to our industry. What legacy are we leaving? Are we truly putting patients first, or merely paying lip service to the idea? GSK's brief but impactful presence in India's oncology market wasn't just a business move - it was a masterclass in ethical leadership and market transformation. Their departure left a void that echoes with missed opportunities and unfulfilled potential. Let this memory serve not just as a nostalgic throwback, but as a rallying cry. The path has been shown. Who among us will have the courage to follow it? #GSK #Oncology #patientcentricity

57

4 Comments

Representation in #ClinicalTrials matters and every patient should have the opportunity to access treatments that could better their lives. That’s why we at AbbVie are working hard to improve representation and diversity in clinical trials. See the bold steps they’re taking to drive systematic change: https://lnkd.in/gQ5cbvnZ #ClinicalTrialsDay #WeAreAbbVie

13

It’s time for pharma to rethink deployment models to meet evolving customer needs, as customer engagement preferences for both channel and frequency continue to change. My colleagues Scott Cohen and Megan Jackson take a closer look at declining access trends, address some of the top field deployment questions and offer tangible steps to evolve sales planning efforts. #oncology #pharma #futurecommercialmodel https://lnkd.in/eMEqApbn

12